Recently, the 2025 Science and Technology Innovation and Industrial Innovation Conference and the Golden Bull Sci-Tech Award Ceremony, organized by China Securities Journal, was officially held in Shanghai. Thanks to its outstanding technological innovation and strong market performance in the biopharmaceutical sector, AccuMedical stood out among numerous candidates and was honored with the 2025 Golden Bull Award for Sci-Tech Innovation Enterprise (Biopharmaceuticals).&nbsp;<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2025/06/19/w36ect0phi.jpg"></figure>&nbsp;This year’s Golden Bull Sci-Tech Awards focused on the theme of technological innovation, highlighting eight strategic emerging industries: next-generation information technology, artificial intelligence, aerospace, new energy, new materials, high-end equipment, biopharmaceuticals, and quantum technology. The awards recognize both listed and unlisted companies demonstrating excellence in these areas, promoting the healthy, sustainable, and high-quality development of China’s sci-tech innovation industry. As a signature financial brand created by China Securities Journal, the&nbsp;“Golden Bull Award” is one of the most influential honors in China’s capital market. The Sci-Tech Golden Bull Awards aim to foster new quality productive forces, guide resource allocation, accelerate the integration of technological and industrial innovation, and support the real economy—driving key advancements in China’s emerging high-tech industries. AccuMedical’s recognition with this award highlights its strong investment value in the biopharmaceutical segment.&nbsp;&nbsp;<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2025/06/19/m46c5co6x4.jpg"></figure>&nbsp;Since its establishment, the company has upheld a commitment to technological innovation, dedicated to providing high-quality, cutting-edge medical devices in the field of neurointervention. Its newly upgraded Lattice NEXT, featuring a world-first&nbsp;“non-extended” tipless guidewire design, utilizes cobalt-chromium alloy, a proprietary mechanical balloon delivery system, and MIROR surface modification technology—filling multiple domestic technological gaps. These advancements enable smoother navigation and more controlled deployment, especially in challenging tortuous vessel cases during the treatment of intracranial aneurysms. Through breakthrough innovations, Lattice NEXT significantly reduces procedural complexity, shortens operation time, enhances patient outcomes, and improves surgical safety, representing a major leap forward in neurointerventional technology and addressing unmet clinical needs.To date, AccuMedical has obtained NMPA approvals for 9 products, including Lattice and Lattice NEXT, and has filed 132 patent applications, with 73 patents granted. In 2023, the company was recognized as a National High-Tech Enterprise, and in 2024, it was selected as a National-level “Little Giant” Enterprise for its specialization and innovation.Looking ahead, AccuMedical will continue to deepen its focus in the neurointervention field, guided by technological innovation. The company will further increase R&amp;D investment, expand its product portfolio, and enhance product performance, striving to deliver superior products and services to patients and physicians worldwide. At the same time, AccuMedical will actively collaborate across industry, academia, research, and clinical practice to drive joint innovation, tackle core technological challenges in neurointervention, and elevate China’s medical device innovation capabilities and global competitiveness—contributing to the high-quality development of China’s neurointerventional medical device industry.

AccuMedical Wins the 2025 “Golden Bull Award for Sci-Tech Innovation Enterprise” — Another Strong Recognition of intelligent manufacturing in China!

Recently, Beijing Municipal Commission of Development and Reform officially released the Catalog of Beijing’s 2025 First Batch of First Units (Sets) of Major Technical Equipment. AccuMedical’s Lattice NEXT Flow Diverter was successfully selected for inclusion.&nbsp;<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2025/06/10/3pp70bfs0mh.jpg"></figure>&nbsp;To be included in the catalog, products must undergo a rigorous process, including formal review, expert evaluation, on-site verification, deliberation by the Expert Advisory Committee, joint departmental review, and final approval by the municipal government. Selected products must demonstrate significant technological breakthroughs, play a key role in the industrial value chain, and have a strong driving force for industrial development. Lattice NEXT’s inclusion in the "Pharmaceutical and Healthcare - Medical Devices - Passive Implantable Devices" the Catalog of Beijing’s 2025 First Batch of First Units (Sets) of Major Technical Equipment (Pharmaceutical and Healthcare and Other Fields) represents a high-level recognition of its advanced technology and market value.AccuMedical’s Lattice NEXT features an innovative&nbsp;“non-extended” guidewire tip design and an optimized stent delivery system, enabling smoother navigation and more controlled deployment, particularly in complex intracranial aneurysm cases involving tortuous vessels. With its groundbreaking technological innovations, both the Lattice and Lattice NEXT significantly reduce the complexity of surgical operations, shorten procedure times, improve patient outcomes, and enhance surgical safety&nbsp;— marking a new era of&nbsp;“automatic mode” in intracranial aneurysm treatment. The devices have already been adopted and used in multiple hospitals, receiving widespread acclaim from clinicians. As the difficulty of procedures is reduced, these treatments are becoming more accessible to remote and county-level hospitals, empowering younger physicians to perform aneurysm procedures with this stent and truly meeting urgent clinical needs.Since its founding, AccuMedical has regarded technological innovation as its core competitiveness. To date, nine products including Lattice and Lattice NEXT have been approved by the NMPA. The company has filed 132 patent applications, of which 73 have been granted. AccuMedical was recognized as a National High-Tech Enterprise in 2023 and as a National-level&nbsp;“Little Giant” Enterprise in 2024. Moving forward, AccuMedical will take this honor as a new starting point to continue its innovation in the field of neurointervention and to contribute to the protection of human health.

AccuMedical’s Lattice NEXT Flow Diverter Selected for Beijing’s Catalog of First Units (Sets) of Major Technical Equipment

On May 26, the Beijing China-Germany Industrial Cooperation Development Forum&nbsp;– 2025 China-Germany (EU) Hidden Champions Forum opened at the China-Germany International Conference and Exhibition Center in Shunyi, Beijing.<img src=""><figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/11/9l7cr4x6pf5.png"></figure>China-Germany (China-Europe) Hidden Champions Forum&nbsp;The forum is co-hosted by the People’s Government of Shunyi District, Beijing, and the European Senate of Economy. It is jointly initiated by the International Cooperation Center of the National Development and Reform Commission, the ADWM Academy of German World Market Leaders, and the DEZ German European Center for SME Cooperation in China, under the theme&nbsp;“Collaborative Innovation&nbsp;· Integrated Development.” Over 600 participants—including government officials, academics, and industry leaders from China and abroad—gathered at the event.Among them, nearly 200 high-level politicians, executives of hidden champion enterprises, and representatives of industry organizations traveled to Beijing from overseas, almost doubling the number of international guests compared to the inaugural forum. More than 400 participants from China’s specialized and sophisticated enterprises, innovative SMEs, research institutions, and industrial investment funds actively took part. Over 50 key Chinese and German (China-Europe) enterprises showcased new products, technologies, and application scenarios onsite. This edition of the forum has established an open cooperation platform with broad participation from diverse stakeholders in China and Germany (China-Europe). Enterprises, institutions, industrial parks, and governments engaged in in-depth discussions on topics including technological innovation, industrial development, talent mobility, and information exchange—jointly composing a new chapter of China-Germany (China-Europe) mutually beneficial cooperation.Hidden champion enterprises are globally leading companies in highly specialized market niches. Though they may not be widely known to the public, they play crucial roles in the industrial value chain.On May 27, the special session&nbsp;“Hidden Strength, Sophisticated Innovation: China’s&nbsp;‘Little Giants’ in Dialogue with Global Hidden Champions” was successfully held. As a flagship event under the Beijing China-Germany Industrial Cooperation Development Forum&nbsp;– 2025 China-Germany (China-Europe) Hidden Champions Forum, it gathered German hidden champion enterprises from over 20 specialized sectors such as biopharmaceuticals, as well as Chinese specialized and sophisticated enterprises across more than 30 industries including intelligent equipment and smart connected new energy vehicles. The event facilitated mutual learning and the exchange of development experience. As the&nbsp;“hidden strength” of China-Germany (China-Europe) enterprises meets&nbsp;“sophisticated innovation,” the transformation journey from&nbsp;“small and excellent” to&nbsp;“strong and refined” is being revealed.<img src=""><figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2025/05/30/3ozsxq9xnqb.png"></figure>Walter Döring, Executive Chairman of the European Senate of Economy and Chairman of the Organizing Committee of the German Global Market Leaders Summit (World Hidden Champions), personally hosted the sub-forum.&nbsp;This event was co-hosted by the DEZ German European Center for SME Cooperation in China and the Shunyi District Bureau of Economy and Information Technology, and organized by Dez Commercial Management (Beijing) Co., Ltd. and Beijing DEZ International Culture Development Co., Ltd. on the successful experiences of the German Global Market Leaders Summit and upholding the summit's spirit, the event was themed&nbsp;“Learn from the Best!” and aimed to build a dialogue and exchange platform between Chinese and German (China-Europe) hidden champions and specialized and sophisticated enterprises. Walter Döring, in his dual role as Executive Chairman of the European Senate of Economy and Chairman of the Summit Committee, personally presided over the session.<img src=""><figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2025/05/30/3wgb4pwfhab.png"></figure>Cui Xiaohao, Deputy Secretary of the CPC Shunyi District Committee and District Mayor, Delivers a Speech&nbsp;At the event, Cui Xiaohao, Deputy Secretary of the CPC Shunyi District Committee and District Mayor; Johannes Hahn, former EU Commissioner for Budget and Administration; Shi Mingde, President of the Chinese-German Friendship Association and former Chinese Ambassador to Germany; Adrian Digolean, Deputy Minister of Agriculture of Moldova; Yang Chonghui, Director of the 12th CPPCC Committee for Hong Kong, Macao, Taiwan, and Overseas Chinese Affairs and former Vice Chairman of the China Economic and Social Council; Feng Bile, former CEO and Supervisory Board Chairman of Siemens and former Chairman of the Asia-Pacific Committee of German Business (APA); Edin Durakovic, Minister of Economy of Tuzla Canton, Bosnia and Herzegovina; and Yang Ming, Vice President of the European Senate of Economy and Executive Chairman of DEZ German European Center for SME Cooperation in China, attended the forum and delivered speeches.<img src=""><figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2025/05/30/amhyn95n42r.png"></figure>Guests Listening to Speeches<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/11/rnryxjp52v.png"></figure>Roundtable Dialogue: Hidden Champions and Specialized and Sophisticated Enterprises in Dialogue&nbsp;Fourteen representatives from Chinese and German (China-Europe) companies and experts shared their insights and experiences in enterprise management, technological innovation, and market expansion, jointly exploring the integration of German craftsmanship with Chinese digital innovation. Participants included Germany’s Ziehl-Abegg Group, renowned in the field of fan and motor manufacturing, and Mainline Technology, a leading Chinese company in L4-level AI truck development and application. German and European hidden champion enterprises such as Alpha-Test, Stealth Startup, Senior Connect, Gessmann, and GEOSAFE engaged in in-depth discussions with representatives from China’s specialized and sophisticated enterprises in niche sectors, including AccuMedical and Wanji Technology in Shunyi District. Topics included&nbsp;“mutual learning,” “technological breakthroughs,” “ecosystem co-construction,” and&nbsp;“global cooperation.”Yu Shuli, Director of Public Affairs at AccuMedical, stated:&nbsp;“As a national-level&nbsp;‘Little Giant’ enterprise specializing in neurointervention, AccuMedical hopes to establish deep cooperation with German hidden champion companies in key areas of the industrial chain such as advanced metal materials and precision manufacturing equipment. At the same time, AccuMedical is actively pursuing EU certification and looks forward to using Germany as a springboard to expand into the European market, so that Chinese innovations can truly serve patients around the world.”The success of German and European hidden champions in niche market focus, continuous innovation, and global expansion provides valuable reference for the internationalization of China’s specialized and sophisticated enterprises. In turn, China’s specialized and sophisticated enterprises showcased their efforts in digital innovation and industrial upgrading, highlighting the innovation vitality and vast opportunities of the Chinese market. This event helped China’s specialized and sophisticated enterprises broaden their international perspectives while painting a promising picture for German and European investment in China.<img src=""><figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2025/05/30/u0exy609njj.png"></figure>Signing of the&nbsp;“Memorandum of Cooperation on Promoting Hidden Champions and Specialized and Sophisticated SMEs between China and Germany (China-Europe)”&nbsp;Following the discussions, the DEZ German-European Center and the European Senate of Economy, along with representatives from the Ministry of Energy of Bulgaria, the Ministry of Agriculture of Moldova, the Chamber of Commerce and Industry of Bosnia and Herzegovina (IHK), and other relevant ministries and institutions, jointly signed the&nbsp;“Memorandum of Cooperation on Promoting Hidden Champions and Specialized and Sophisticated SMEs between China and Germany (China-Europe)”. The memorandum aims to establish a long-term cooperation mechanism in areas such as economic and trade collaboration, technology exchange, and talent development, fostering complementary strengths and coordinated development.Looking ahead, Shunyi District will leverage the development of the Beijing China-German Economic and Technological Cooperation Demonstration Zone to attract more German and European hidden champion enterprises to cluster and grow. The district aims to become a key hub for the practical implementation of the China-German Economic and Technological Cooperation Forum mechanism, a vital platform for two-way economic and technological collaboration between China and Germany (China-Europe), and a major gathering place for hidden champions and innovative enterprises from both sides. This initiative will promote deeper integration of enterprises into the regional industrial chain, supporting industrial upgrading and fostering high-quality economic development.

2025 China-Germany (China-Europe) Hidden Champions Forum Opens, AccuMedical Represents China’s “Little Giant” Enterprises in Dialogue with Global Hidden Champion

<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/a4zk8szeaqa.png"></figure>On May 17, 2025, during the highly anticipated WLNC x OCIN2025 International Neurointervention Conference, the global launch of the new-generation "tipless" mechanical balloon-assisted flow diverter system—Lattice NEXT—was grandly held, along with the 045 Flow Diverter Technique Forum for Complex Aneurysm Treatment. As a trailblazer in the industry, AccuMedical once again broke new ground, presenting a comprehensive solution from novel flow diverter designs to innovative access technologies, and joined neurointerventionalists in exploring the future paradigms of neurointerventional therapy.&nbsp;Discussion · Pursuing Precision, Setting New Heights Opening RemarksProf. Yi Xu from Shanghai Changhai Hospital, Chairman of the conference, noted in his opening address: “Lattice, as a domestically developed flow diverter, has achieved significant market share in a short time and gained international recognition, which is no coincidence. Innovation is a vital driving force. By continuously uncovering clinical needs, AccuMedical has made breakthrough after breakthrough, and now proudly presents Lattice NEXT—a revolutionary product that builds on the precision of the original flow diverter and upholds intraoperative safety. I believe it will bring further clinical advancements to neurointerventionalists. Looking ahead while refining from within, we aim to contribute to the future of precision medicine.”<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/ywmh8qhvf6h.png"></figure>&nbsp;Listen · The Voice of Innovation, Reinventing the Field Opening KeynoteProf. Chuan He from Xuanwu Hospital, Capital Medical University, emphasized that neurointervention has entered the era of flow diversion. Flow diverters have evolved through three generations: First-generation Nitinol stents (e.g., Silk) were phased out due to high complication rates. Second-generation cobalt-chromium stents (e.g., Pipeline) brought significant safety and efficacy improvements. Third-generation devices, including domestic innovations like Lattice, feature advanced designs such as tipless structure and mechanical balloon assistance to overcome operational challenges. Future trends will include full-length visibility, anti-kinking cobalt-chromium materials, surface modifications to reduce thrombosis, smaller systems (e.g., 17 system), and expanded radial access use.The Lattice NEXT combines tipless structure, mechanical balloon, MIROR technology, and cobalt-chromium alloy to greatly enhance distal vessel compatibility and safety. Clinical case demonstrations showed excellent performance in tortuous vessels, full expansion, and high cure rates. For complex aneurysms, four bridging stents significantly reduced postoperative hemorrhage risk. Ultimately, the core of neurointervention lies in simplicity, safety, and efficacy—and domestic devices like Lattice are propelling this evolution.<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/p0uh94zojlj.png"></figure>&nbsp;Insight · What Is a “Tipless” Flow Diverter NEXT Launch · Academic Case ApplicationsThis session was moderated by Prof. Guobiao Liang from the General Hospital of Northern Theater Command and Prof. Huaizhang Shi from the First Affiliated Hospital of Harbin Medical University.<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/t32q0z8mtdp.png"></figure>Tipless Design: A Safety Key for Distal LesionsProf. Ge Gao from the First Affiliated Hospital of University of Science and Technology of China found that in treating large aneurysms at the cavernous segment, the tipless design helps avoid damage to branch vessels caused by distal guidewire tips. Prof. Yang Zhao from Peking University International Hospital confirmed through complex ophthalmic artery cases that the stent can still be stably released even with a shortened wire, significantly enhancing surgical safety. Prof. Gang Xu from the Second Affiliated Hospital of Xi’an Jiaotong University noted that in challenging anterior communicating artery aneurysms, the tipless design greatly reduces procedural risks across vessels.Mechanical Balloon Enables Precision DeploymentCombining cobalt-chromium alloy with mechanical balloon design is a key differentiator for Lattice. Prof. Jun Sun from Nanyang Central Hospital observed that the system ensures perfect wall apposition in tapered vessels. Prof. Gao added that the balloon's push force allows for multi-stent bridging in wide-neck aneurysms. Prof. Zhao emphasized that the improved delivery system provides smoother navigation through the ophthalmic bend.Intelligent Sizing Reshapes Preoperative PlanningProf. Sun introduced the Lattice sizing mini-program, which accurately recommends stent specifications based on vessel diameter and length—greatly simplifying surgical planning. Prof. Gao highlighted its utility in determining coverage for multi-aneurysm cases. Prof. Xu affirmed that intelligent sizing helps clinicians make better decisions in complex anatomies like the anterior communicating artery.Broad Indications Meet Clinical NeedsClinical data show that the Lattice series has been successfully used across a wide range of cases, from routine to complex. Profs. Gao and Sun shared strong outcomes in wide-neck aneurysms and dissections. Prof. Xu demonstrated advantages in managing multiple aneurysms. Prof. Zhao pointed out that the tipless design expands its application to high-risk scenarios like stenotic or bifurcated lesions.Domestic Innovation Breaking Through Technical BarriersFrom its first to second generation, the Lattice system showcases the innovative strength of domestic medical devices. Prof. Sun stressed that close collaboration between R&amp;D and clinicians allows for rapid response to clinical needs. Through international comparisons, Profs. Gao and Xu confirmed that Lattice performs on par with imported stents in complex cases.<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/uo3wbh3frem.png"></figure>Prof. Ge Gao, First Affiliated Hospital of USTC<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/z8m4kgkzt9.jpg"></figure>Prof. Gang Xu, Second Affiliated Hospital of Xi’an Jiaotong University<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/2e09hhnkaj9.jpg"></figure>Prof. Yang Zhao, Peking University International Hospital<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/j9db9vug2r8.jpg"></figure>Prof. Jun Sun, Nanyang Central HospitalAfter the Lattice NEXT academic talks, experts shared in-depth insights on the tipless design and debated hot issues in flow diverter therapy. Prof. Wanchao Shi from Tianjin Fifth Central Hospital praised the design for enhancing intraoperative safety and offering more options for complex aneurysms. Prof. Xianliang Lai from Second Affiliated Hospital of Nanchang University shared that in large-diameter, tortuous aneurysms requiring long stents, he prefers Lattice for its superior wall apposition and unfolding performance. Prof. Maimaiti Aisha from First Affiliated Hospital of Xinjiang Medical University noted Lattice’s unique advantages in positioning, deployment, and apposition. Prof. Xiang Xu from Tangshan Workers’ Hospital emphasized the tipless design’s benefit in enhancing delivery stability. Prof. Yunbao Guo from First Hospital of Jilin University led a discussion on overlapping flow diverters for blister aneurysms. Both Profs. Liang and Shi suggested caution, calling for more clinical evidence.<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/xoeky7r8iu8.png"></figure>&nbsp;Battle · Solid Pathway, Led by the 045 045 Flow Diverter Technique · Practical SessionThis academic session was jointly chaired by: Prof. Zuoquan Chen, Tenth People’s Hospital of Tongji University, Prof. Chuanzhi Duan, Zhujiang Hospital of Southern Medical University, and Prof. Qingdong Guo, Xijing Hospital, Air Force Medical University<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/pxr1s31fas.png"></figure>High Positioning Solves Access ChallengesProf. Qinghai Huang from Shanghai Changhai Hospital shared a case involving multiple aneurysms (MCA, lenticulostriate artery, and posterior communicating artery). He innovatively built a coaxial system using Cosine45 intermediate catheter and 27 microcatheter, successfully navigating tortuous vessels to reach the proximal MCA, thus laying a strong foundation for stent delivery. Prof. Chun Chen from First Affiliated Hospital of Kunming Medical University noted that when Cosine45 was placed only at the C6 segment, stent delivery failed; after advancing to M2 using the "Trojan Horse technique", the 4.1mm×45mm Lattice stent was successfully deployed. Both emphasized that proactive distal access is key for tortuous lesions.Intermediate Catheter Solves Stent KinkingProf. Huang demonstrated two key values of Cosine45:<ul><li style="text-align:justify;">During positioning, millimeter-precise release can be achieved by catheter retraction</li><li style="text-align:justify;">If kinking occurs, push-pull manipulation along the catheter outer wall effectively untwists the stent These techniques are particularly beneficial for tandem aneurysms—ensuring accurate initial stent coverage and space for subsequent embolization.</li></ul>Compatibility Design Expands Treatment BoundariesBoth experts noted that a 6F long sheath can simultaneously accommodate Cosine45 and coil delivery catheters, enabling both standalone flow diverters and combined stent-coil surgeries. Prof. Huang emphasized that the 4.6F small outer diameter allows deep vessel navigation previously unreachable by traditional intermediate catheters. Introduction of the 17 system further minimizes vascular trauma.<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/77oz17e89k4.jpg"></figure>Prof. Qinghai Huang, Shanghai Changhai Hospital<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/lqhdln4ucc.jpg"></figure>Prof. Chun Chen, First Affiliated Hospital of Kunming Medical UniversityProf. Lei Wang from Yichang Central People’s Hospital praised Cosine45's 4.6F design for balancing high positioning and compatibility, showing potential value in complex aneurysms. Prof. Shijie Na from Nanjing Drum Tower Hospital added that Cosine45 supports techniques like the Trojan Horse. Prof. Guohua Mao from Second Affiliated Hospital of Nanchang University shared how Cosine45 combined with Neuromax long sheath resolved complex access challenges. Prof. Zhixin Zhao from Taizhou Hospital stressed that an ideal intermediate catheter should offer both support and flexibility—qualities well-reflected in Cosine45. Now, Cosine45 has evolved from a simple access tool to an intelligent system that actively participates in stent deployment. As Prof. Chen said:“Proactive protection is better than passive correction”—a philosophy that is redefining the standard neurointervention workflow.Prof. Chen concluded by affirming Cosine45’s impressive performance in complex aneurysm procedures and its clinical value.<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/e18syvbizw.png"></figure>&nbsp;Solve · The Ultimate Challenge of Complex Aneurysms Lattice Innovative Flow Diverter Case ApplicationThis academic session was moderated by: Prof. Zhenbao Li, Yijishan Hospital of Wannan Medical College, and Prof. Changming Wen, Nanyang Central Hospital<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/wkowlc7gwtl.png"></figure><figure class="image"><img></figure>Mechanical Balloon Solves Tortuous Vessel ChallengeProf. Xiaochuan Huo from Anzhen Hospital, Capital Medical University, treated a case of bilateral ICA multiple aneurysms with extremely tortuous vessels. The mechanical balloon of the Lattice system proved essential. Even with insufficient support from a 5F intermediate catheter, 4.4mm×15mm and 4.7mm×35mm stents were successfully deployed in segments. Prof. Zhihua Du from PLA General Hospital highlighted the mechanical balloon’s ability to prevent wire over-advancement, ensuring accurate release. Prof. Xinguo Li from First Affiliated Hospital of China Medical University showed that even after retrieval due to kinking, the balloon preserved structural integrity upon second deployment.Wide Indications &amp; Long-Term OutcomesProf. Du’s single-center data (46 patients, 56 aneurysms) showed excellent performance in saccular, fusiform, and dissecting aneurysms, with a 6-month cure rate of 72%. Prof. Huo’s follow-up data (up to 1 year) confirmed reliable apposition and vessel remodeling even in stenotic, tortuous lesions.Innovative Design Brings Technical HighlightsAll three speakers emphasized the following Lattice features:<ol><li style="text-align:justify;">No distal wire jump: Reduces perforator injury risk in areas like basilar apex</li><li style="text-align:justify;">Precise foreshortening control: A 5.6mm×39mm stent maintained cylindrical shape in a 40mm dissecting aneurysm</li><li style="text-align:justify;">Anti-kinking performance: Stent remained structurally intact after re-release, with unaffected flow diversion</li></ol><figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/q9h6gkz09pc.jpg"></figure>Prof. Xiaochuan Huo, Anzhen Hospital<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/sc2hpmwrx4p.jpg"></figure>Prof. Zhihua Du, PLA General Hospital<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/cs3k6d0y21t.jpg"></figure>Prof. Xinguo Li, First Affiliated Hospital of China Medical UniversityIn closing, discussion panelists shared their perspectives on Lattice &amp; Lattice NEXT: Prof. Shenghao Ding from Renji Hospital, Shanghai Jiao Tong University, highlighted excellent wall apposition in tortuous and large aneurysms, further improved with Cosine45. Prof. Guoliang Jiang from Kunming Medical University emphasized the enhanced deliverability of the new tipless design. Prof. Shenghui Xiao from Nanhai District People’s Hospital in Foshan stressed the importance of balloon-assisted deployment and precise sizing. Prof. Yunfeng Zhang from Affiliated Hospital of Nantong University suggested individualized strategies for cases with concurrent stenosis. Prof. Shiwei Du from South China Hospital, Shenzhen University, confirmed through long-term follow-up that Lattice supports durable aneurysm healing. The panel agreed: domestic innovations like Lattice are reshaping the clinical future of neurointervention.<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/uofh2qgq7bb.png"></figure>&nbsp;

WLNC x OCIN2025 | Lattice NEXT Launch Event & 045 Flow Diverter Forum Highlights

The 27th China Beijing International High-Tech Expo (referred to as the&nbsp;“Beijing CHITEC”) recently concluded successfully. Under the theme&nbsp;“Technology Empowering a Creative Future,” this year’s event featured six thematic exhibition zones: Information Technology, Intelligent Manufacturing, Pharmaceuticals &amp; Healthcare, Green &amp; Carbon Neutrality, Digital Economy, and Regional Innovation. More than 800 enterprises and institutions from both China and abroad participated in the exhibition.As a national platform for global exchange and cooperation in science and technology innovation, the forum focused on&nbsp;“New Quality Productive Forces and Global Technological Cooperation.” It explored cutting-edge technology and industry development trends and facilitated discussion on how innovation can cultivate new quality productive forces, offering new ideas for global innovation and development.AccuMedical Beijing Ltd., a prominent representative in the field of neurointervention, showcased its core product&nbsp;— Lattice Flow Diverter&nbsp;— as well as the newly upgraded Lattice NEXT Flow Diverter featuring a&nbsp;“no extended tip guidewire” design for 2025. The exhibition fully demonstrated the innovation strength and clinical achievements of Chinese enterprises in neurointervention, attracting extensive attention from domestic and international science and technology enthusiasts, professionals, and investors.<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/dcrzprvnc8i.png"></figure>Flagship Products Take Center Stage, Innovation RecognizedAt the Shunyi Exhibition Zone, AccuMedical’s booth became a major highlight. The Lattice Flow Diverter, known for its precise implantation, brings new hope to patients with intracranial aneurysms. Made of cobalt-chromium alloy, this product is equipped with the world’s first mechanical balloon delivery system and MIROR surface modification technology&nbsp;— groundbreaking innovations that fill several domestic gaps. It significantly reduces surgical complexity, shortens procedure time, and improves patient recovery and safety, ushering in the&nbsp;“automatic gear” era of aneurysm treatment.Currently, the Lattice has been adopted in over 500 hospitals across China. It has earned widespread recognition from clinicians and is gradually expanding to remote and county-level hospitals, enabling more patients in underserved areas to benefit from advanced treatment.<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/fextziu4jj.png"></figure>Technology Empowers Healthcare: Delivering&nbsp;“Chinese Wisdom” to the WorldDuring the expo, AccuMedical provided a comprehensive overview of its core technologies and clinical achievements, offering a uniquely&nbsp;“Chinese solution” for intracranial aneurysm treatment. Technology-driven innovation has always been the company’s core competitiveness. So far, nine of its products&nbsp;— including Lattice and Lattice NEXT&nbsp;— have been approved by the NMPA, with 132 patent applications filed, 73 of which have already been granted. The Lattice Flow Diverter was designated an&nbsp;“Innovative Medical Device” by the NMPA and fast-tracked for approval through the “Green Channel”. AccuMedical was recognized as a National High-Tech Enterprise in 2023 and selected as a National-level&nbsp;“Little Giant” Enterprise in 2024. Its innovation capabilities and clinical performance continue to earn industry-wide acclaim.<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/1uzn4a48etb.png"></figure>Deepening Collaboration to Shape the FutureDuring the expo, AccuMedical engaged in in-depth exchanges with numerous experts, scholars, and industry representatives, sharing its latest research and technological developments in neurointervention. Through active cooperation, the company continues to explore innovations aimed at providing a comprehensive portfolio of neurointervention solutions to physicians and patients worldwide. Its mission is to promote&nbsp;“real innovation for real application” in the localization of medical devices and address unmet clinical needs in cerebrovascular care.<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/85hzkd7b2p2.png"></figure><figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/pnn0ilhcyo.png"></figure>Additionally, over 20 international students from Tsinghua University’s School of Public Policy and Management visited the Shunyi Exhibition Zone. They participated in cultural exchanges, scientific discussions, and project matchmaking with exhibitors like AccuMedical, opening new doors for global collaboration. A representative from AccuMedical stated that the company will continue increasing investment in R&amp;D and launch more internationally competitive medical devices to provide higher-quality treatment options for patients worldwide and to contribute to the high-quality development of China’s medical device industry.<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/u0h1m6pglz.png"></figure><figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/z9nriba8a1.png"></figure>&nbsp;

2025 Beijing International High-Tech Expo Successfully Concludes: A Glimpse into AccuMedical’s Highlights

On April 18, 2025, the high-level academic conference "The Game Changer&nbsp;— 045 Flow Diverter Guard Technology Launch &amp; Master Forum on Flow Diverter Treatment of Complex Aneurysms with Mechanical Balloon" was successfully held as part of the 22nd China Forum on Cerebrovascular Disease (CFCVD2025). This session focused on the application of innovative access technologies and explored the clinical use of flow diverters in complex cases. Experts jointly envisioned a new blueprint for the neurointervention field, contributing their insights to promote academic advancement and technological innovation.<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/f2bx1dqctx6.png"></figure>&nbsp;Opening AddressInnovating Through Tradition, Advancing Precision in Cerebrovascular Interventions TogetherProf. Zhang Hongqi, chairman of the conference, stated that since the introduction of flow diverters in hemodynamic therapies, AccuMedical has brought innovative products demonstrating unique advantages in clinical practice. With the support of advanced catheter systems, flow diverter deployment has become simpler. All types of flow diverters emerging on the market reflect the principle that clinical demand drives technological innovation. While maintaining its core competencies, AccuMedical continuously launches new technologies to make neurointerventional procedures easier, more accessible, and more precise. Looking forward, with collective efforts, neurointervention and interventional technology will continue to break new ground, jointly advancing the precision of cerebrovascular intervention.&nbsp;<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/7ny09btp3uh.png"></figure>Zhang Hongqi, Xuanwu Hospital Capital Medical University&nbsp;PART I045 Flow Diverter Guard Technology for Complex AneurysmsRevolutionizing Access, Enhancing Clinical OutcomesCosine45 Intermediate Microcatheter&nbsp;– A new option for 045 Flow Diverter Guard!This session was co-chaired by Prof. Chen Zuoquan (Tenth People's Hospital of Tongji University), Prof. Gu Yuxiang (Huashan Hospital Fudan University), and Prof. Yang Xinjian (Beijing Tiantan Hospital, Capital Medical University).1. Key Factors for Precise Flow Diverter DeploymentBoth Prof. He Chuan (Xuanwu Hospital Capital Medical University) and Prof. Liu Lian (Beijing Tiantan Hospital, Capital Medical University) emphasized that access support and stability are critical for precise deployment. The 045 Flow Diverter Guard Technology addresses these issues well. For instance, when treating an A2 segment anterior cerebral artery aneurysm, traditional access is challenging, while Cosine45 can directly reach the A1 segment, offering strong support and stability at the aneurysm neck and tortuous vessels, preventing stent displacement or poor wall apposition.2. Ideal Partner for Complex AneurysmsProf. Liu Lian shared a case involving Lattice combined with Cosine45 for treating a giant aneurysm. In this case of tortuous parent artery, the Cosine45 intermediate catheter’s design allowed for smoother dual Lattice deployment and apposition.3. Excellent CompatibilityProf. He Chuan noted that traditional access often involves time-consuming device exchanges. The 045 Flow Diverter Guard Technology minimizes such issues and enables safer deployment of the flow diverter when coaxially positioned with a 27 microcatheter.4. Radial Approach OptimizationProf. Zhong Shu (Guangxi Hospital Division of The First Affiliated Hospital, Sun Yat-sen University) highlighted that Cosine45 is highly suited for radial flow diverter deployment due to its superior flexibility, kink resistance, and distal reach. It easily traverses the aortic arch and provides stable support, greatly facilitating the procedure.&nbsp;<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/sbaprr80qi.png"></figure>He Chuan, Xuanwu Hospital Capital Medical University&nbsp;<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/65x5e1cpbn5.png"></figure>Zhong Shu, Guangxi Hospital Division of The First Affiliated Hospital, Sun Yat-sen University&nbsp;<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/qe367d74ka.png"></figure>Liu Lian, Beijing Tiantan Hospital, Capital Medical University&nbsp;In the first panel discussion, the guest panelists engaged in a lively conversation with the speaker on the following topics:&nbsp;1. Distal Flow Diverter DeploymentProf. Qi Peng (Beijing Hospital) discussed with Prof. He Chuan the use of the Cosine45 in scenarios involving deployment of the flow diverter at the A1 segment using a 17 microcatheter. Prof. He Chuan noted that navigating a 27 microcatheter through the flow diverter in this region could be challenging, making the 17 system a more suitable choice. Among various intermediate catheters, the Cosine45 offers better compatibility with the 17 system, ensuring smoother delivery. He further emphasized that the Cosine45 supports surgeons in establishing access to complex distal aneurysms, laying a solid foundation for successful procedures.2. Discussion on Support Performance of Flow Diverter Deployment via Radial AccessProf. Wang Dengliang (The First Affiliated Hospital of Fujian Medical University) stated that radial access for aneurysm treatment is increasingly mature, and Cosine45 provides improved support and stability compared to traditional intermediate catheters.3. More Possibilities for Access CombinationsAccess combinations are highly variable, and the role of intermediate catheters differs across clinical scenarios. Prof. Chen Zuoqian (Tenth People's Hospital of Tongji University) and Prof. Liu Lian shared their views on using 6F/5F intermediate catheters following either an 8F guiding catheter or a 6F long sheath. Using the Cosine45 intermediate catheter within a 6F system provides greater stability in establishing the access pathway, though it may also increase resistance during system advancement. In practical application, however, the support strength of Cosine45 indeed helps to mitigate this issue. Prof. Cheng Meixiong (Sichuan Provincial People’s Hospital) discussed the access strategy for FD+Coil dual systems with Prof. Liu Lian.Prof. Zhou Xiaobing (The First Affiliated Hospital of Nanchang University) pointed out that releasing a flow diverter—especially those made of cobalt-chromium alloy—requires a more supportive access system. Currently, their center predominantly uses 6F systems, but the advent of the innovative 4.6F Cosine45 intermediate catheter allows for better assistance in deploying flow diverters in distal aneurysms and in techniques such as the&nbsp;“Trojan Horse” method. Prof. Wang Yang (Beijing Chao-Yang Hospital) explored the possible applications of Cosine45 in terms of its length, and Prof. Hu Xuebin had an in-depth discussion with Prof. Liu Lian about a complex aneurysm bridging case using a flow diverter.Finally, Prof. Wang Jun (Chinese PLA General Hospital) shared insights through a clinical case using Cosine45: treating a large A3 segment aneurysm with a flow diverter, supported by the 045 Flow Diverter Guard technique. The system facilitated smooth microcatheter positioning. During microcatheter retraction for releasing an intrasaccular flow-disruption device, Cosine45 provided stable support for the entire system.After this engaging first discussion session, Prof. Yang Xinjian (Beijing Tiantan Hospital, Capital Medical University) concluded that the Cosine45-enabled 045 Flow Diverter Guard technique is poised to become a powerful tool for treating distal aneurysms, complex aneurysms, and facilitating flow diverter deployment via radial access. It offers a new option and future direction for aneurysm treatment.&nbsp;PART IILattice for Complex AneurysmsCase Studies and Experience SharingUntangling Complexity&nbsp;— Expanding the Possibilities of Flow Diverter TherapyChaired by Prof. Li Tianxiao (Henan Provincial People’s Hospital) and Prof. Wang Jun (Chinese PLA General Hospital).1. Representative Cases &amp; Core ChallengesProf. Zhang Qingrong (Drum Tower Hospital, Nanjing University) presented a case of intracranial aneurysm during pregnancy, managed with stage-one coiling and stage-two Lattice implantation after ethical discussions.Prof. Dong Yushu (Northern Theater General Hospital, PLA) performed awake treatment for a right A2 segment aneurysm, testing both stent delivery and opening performance.2. Treatment Strategy &amp; Technical AdvantagesProf. Feng Jun (Union Hospital, Tongji Medical College, Huazhong University of Science and Technology) presented a case of vertebral artery dissection aneurysm treated with Lattice. Accurate placement was critical to avoid basilar artery impact. Post-deployment angiography showed smooth blood flow and good wall apposition, highlighting Lattice’s precise positioning capability.3. Dual-Stent X ConfigurationProf. Chen Wenhuo (Union Hospital, Fujian Medical University) and Prof. Chen Fajun (Guangdong Provincial Hospital of Traditional Chinese Medicine) each shared cases involving X-shaped dual Lattice stents for anterior communicating artery aneurysms. The aneurysms were fusiform, involving both A1 and A2 segments bilaterally, with wide necks and irregular morphology. A Type III arch and tortuous paths made simple wire navigation difficult. The X-shaped dual-stent strategy ensured effective treatment and reduced procedural difficulty.4. Clinical Outcomes &amp; Follow-UpProf. Chen Fajun presented single-center Lattice follow-up data. Compared to other FDs, Lattice showed clear advantages in delivery, retrievability, and model diversity. Among 30 patients, 33 aneurysms, and 34 stents, most aneurysms showed complete occlusion or marked improvement at 1, 6, 9, and 12-month follow-ups. Restenosis was rare, with few complications, and most patients had good postoperative recovery.&nbsp;<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/aianvokk17j.png"></figure>Zhang Qingrong, Drum Tower Hospital, Nanjing University&nbsp;<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/t42rgu5wzis.png"></figure>Dong Yushu, Northern Theater General Hospital, PLA&nbsp;<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/72l67py4pvu.png"></figure>Feng Jun, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology&nbsp;<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/zz3hnk26gx.png"></figure>Chen Fajun, Guangdong Provincial Hospital of Traditional Chinese Medicine &nbsp;<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/rfmb49qqwgh.png"></figure>Chen Wenhuo, Fujian Medical University Union HospitalFollowing the impressive case presentations, the second discussion session featured a lively and intense exchange between the guest panelists and the speakers.Prof. Bai Peng (First Affiliated Hospital, Kunming Medical University) commented on the pregnancy case, suggesting interventional options to preserve pregnancy. Prof. Wang Yunyan (Qilu Hospital, Shandong University) addressed dual antiplatelet concerns. Prof. Gao Ge (First Affiliated Hospital, University of Science and Technology of China) discussed a vertebrobasilar dissection case, advocating minimal stent usage to avoid complications.Experts debated X-shaped deployment techniques:Prof. Gao Ge praised X-configuration for complex anterior communicating aneurysms, emphasizing surgical completeness as key. Prof. Wang Yunyan noted deployment difficulty determines X vs. H configuration. Experts debated catheter placement timing&nbsp;— bilateral vs. sequential.Prof. Li Tianxiao and Prof. Chen Fenghua (Xiangya Hospital, Central South University) discussed indications and contraindications. Prof. Feng Jun emphasized contraindications and summarized Lattice’s broad indications, covering both anterior and posterior circulations.&nbsp;Prof. Li Xifeng (Zhujiang Hospital, Southern Medical University) noted that Lattice’s mechanical balloon allows in-situ deployment and precise positioning—an exciting innovation worth broader adoption.<img>&nbsp;<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/qvyz29bu62.jpg"></figure>&nbsp;Prof. Wang Jun concluded that in aneurysms with stenosis, Lattice’s cobalt-chromium structure proves effective. In vertebral artery cases, the balloon-assisted stent opens without jumping, enhancing surgical safety. These shared experiences have furthered academic exchange and technical progress, offering vital clinical reference in the neurointervention field.

A Full House! — Official Launch of the “045 Flow Diverter Guard Technology” @CFCVD2025

<figure class="image"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2025/04/22/4zysvgc6y64.jpg"></figure>&nbsp;Recently, the SLICE Next Frontiers Conference on Endovascular Stroke Treatment was held in Montpellier, France. AccuMedical made a striking debut with its Lattice NEXT Flow Diverter with Non-Extended Tip Design, joining leading global neurointervention experts to explore the future of flow diversion technologies.At the conference, Professor Liyong Sun from Xuanwu Hospital, Capital Medical University, and Dr. Vincent Costalat, founder of SLICE, engaged in an in-depth discussion on the application of Lattice in the treatment of complex aneurysms.&nbsp;<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2025/04/22/7w6279d6i5.jpg"></figure>Left: Dr. Vincent COSTALAT Hôpital Gui de Chauliac, CHU de MontpellierRight: Professor Liyong SUN Xuanwu Hospital, Capital Medical University&nbsp;In a particularly challenging case involving a cavernous segment aneurysm with a highly tortuous access route, Dr. Vincent Costalat and an international panel of experts discussed the feasibility of optimal treatment strategies. The key challenges in such cases include difficulty in establishing access, difficulty in stent delivery, and even if positioned successfully, risk of device twisting during deployment, making the procedure highly demanding.However, thanks to its innovative "Non-Extended Tip" guidewire design and further-optimized delivery system, Lattice NEXT demonstrated smoother access and easier deployment in tortuous vascular anatomies.&nbsp;<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2025/04/22/a5qmpv1meb7.jpg"></figure>SLICE Discussion Panel&nbsp;Professor Liyong Sun conducted a live demonstration of treating a cavernous segment fusiform aneurysm using Lattice NEXT Flow Diverter, assisted by Cosine45 Intermediate Catheter and Sine27 Microcatheter. The procedure involved advancing the Sine27 microcatheter into the middle cerebral artery, followed by the Cosine45 catheter to cross the aneurysm neck and reach the siphon curve. The advanced delivery system of Lattice NEXT enabled stable and smooth deployment of the stent, preventing device twisting. Once in position, the stent was released with ease. The stent opened smoothly while navigating curves, and intraoperative imaging showed excellent wall apposition!&nbsp;<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2025/04/22/5qgxboiehlp.jpg"></figure><figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2025/04/22/cmbkdyb53xp.jpg"></figure><figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2025/04/22/3l3k91j8crp.jpg"></figure><figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2025/04/22/314l0tiqmah.jpg"></figure>Professor Liyong Sun Treating a Cavernous Segment Fusiform Aneurysm Using Lattice NEXT + Cosine45 + Sine27<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2025/04/22/g1amm5gdcs9.jpg"></figure>Lattice NEXT Showcase&nbsp;About SLICESLICE brings together stroke care professionals from around the world, providing a global platform for academic exchange and learning. It also actively encourages participation from young physicians, blending education with interactive experiences to impart the latest academic knowledge and expert insights.The SLICE Stroke Conferences are held twice a year in Montpellier, France:<ul><li style="text-align:justify;">SLICE Worldwide — the multidisciplinary neurointervention congress in October, and</li><li style="text-align:justify;">SLICE Next Frontiers — the specialized endovascular stroke treatment conference in April.</li></ul>

AccuMedical Shines at the International SLICE Next Frontiers Stroke Conference

Recently, AccuMedical’s latest flow diverter system, Lattice COUPLE, received official registration approval from the National Medical Products Administration (NMPA).Registration Certificate Number: NMPA 20253130668With this milestone, AccuMedical becomes the first company in the neurointervention field to hold three approved flow diverter registration certificates.&nbsp;<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2025/04/11/o99mmf7now.jpg"></figure>&nbsp;

Exciting News! AccuMedical Secures Approval for Its Third Flow Diverter Registration Certificate!

Recently, the 2025 Zhongguancun Forum Annual Conference concluded successfully. At the Permanent Exhibition in the Zhongguancun National Independent Innovation Demonstration Zone Exhibition Center, AccuMedical showcased its self-developed Lattice Flow Diverter and Lattice NEXT Flow Diverter with "Non-Extended Tip Guidewire" in the High-End Medical Device Exhibition Area. The innovations were prominently covered by major central media outlets, including CCTV-13 News Channel’s "News Live Room", CCTV-2 Finance Channel’s "Economic News" and "The First Time", as well as CCTV-4 Chinese International Channel’s "China News".&nbsp;<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/11/8ivgcii4y38.png"></figure><figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/11/2ge95eyp4gj.png"></figure><figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/11/a9bs80ntsms.png"></figure><figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/11/svugful98k.png"></figure><figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/11/6j6dumo2735.png"></figure><figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/11/q18zhwmgu9.png"></figure>&nbsp;As China’s national platform for global exchange and cooperation in technological innovation, this year’s Forum was themed “New Quality Productive Forces and Global Technological Cooperation”, offering deep discussions on cutting-edge science and technology trends and industrial development, while exploring new pathways for fostering innovation-driven productivity to support global progress.&nbsp;<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/11/qob9skkjlwg.png"></figure><figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/11/yl3p8h74pbc.png"></figure><figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/11/n2fezjsbhc.png"></figure><figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/11/gill1kq0v1u.png"></figure>&nbsp;The Permanent Exhibition of the Zhongguancun Forum focused on global scientific frontiers and future industries, featuring over 490 exhibits from more than 350 organizations, including 130+ first-release projects. Highlights included breakthroughs in AI+, humanoid robotics, commercial aerospace, intelligent connected new-energy vehicles, synthetic bio-manufacturing, innovative drugs, and high-end medical devices. The exhibition comprehensively showcased Beijing’s latest achievements in using technological innovation to lead the development of new quality productive forces and build a modern industrial system.&nbsp;<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/11/u7ar8k90x89.png"></figure><figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/11/ed2mdt5aubq.png"></figure>&nbsp;During the Forum, AccuMedical made a strong appearance in the high-end medical device exhibition area with several of its innovative products. This marks the second consecutive year the company has participated in the Zhongguancun Forum, demonstrating its leading innovations driven by technology, and once again attracting key coverage by CCTV. The national spotlight on CCTV is a testament to the attention garnered by AccuMedical’s breakthrough products and a strong endorsement of its R&amp;D capabilities.As a technology-driven medical device company focusing on neurointervention, AccuMedical’s portfolio includes a comprehensive range of interventional and access-related innovative devices for the treatment of both hemorrhagic and ischemic stroke. The Lattice and Lattice NEXT devices, featured in the CCTV coverage, represent major industry innovations.&nbsp;<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/11/5m1zuqv4vpd.png"></figure>&nbsp;The Lattice Flow Diverter, approved via China’s Special Review Procedure for Innovative Medical Devices, is the first to extend the indications of flow diverters to the treatment of medium and small vertebral artery aneurysms, currently the broadest approved indication among similar products. Constructed with cobalt-chromium alloy, and equipped with globally first-in-class technologies such as a mechanical balloon delivery system and MIROR surface modification, Lattice fills several domestic technology gaps. In clinical performance, the Lattice demonstrated a 91.4% aneurysm occlusion rate at 12 months post-operation and an in-stent stenosis rate of just 0.8%, significantly outperforming comparable products.Thanks to these breakthrough innovations, AccuMedical has effectively reduced the technical complexity of procedures for physicians, shortened surgery times, and improved both patient outcomes and procedural safety, marking the beginning of a new “automatic gear” era in intracranial aneurysm treatment. Lattice is now being used in multiple hospitals and has been highly praised by clinicians. With reduced procedural difficulty, its application has extended to rural and county-level hospitals, enabling more young doctors to confidently treat patients using this device—fulfilling real clinical needs.&nbsp;<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/11/v7x06ddmmsf.png"></figure>&nbsp;Since its inception, AccuMedical has positioned technological innovation as its core competitive edge. To date, eight of its products—including Lattice and Lattice NEXT—have been approved by the NMPA, and the company has filed 132 patent applications, with 73 already granted. AccuMedical was recognized as a National High-Tech Enterprise in 2023, and selected as a National-level “Little Giant” Enterprise in 2024.Joining this year's Zhongguancun Forum Permanent Exhibition alongside many other cutting-edge innovations further affirms AccuMedical’s strength in technological innovation. The enthusiasm surrounding the 2025 Zhongguancun Forum reflects how frontier technologies are accelerating toward real-world application and ecosystem development. AccuMedical’s products and solutions illustrate how China’s medical innovators are contributing new momentum to the fight against cerebrovascular diseases, and how new quality productive forces are enhancing the accessibility of innovative medical technologies.&nbsp;

AccuMedical Featured in CCTV News Coverage and Returns to the Permanent Exhibition of the Zhongguancun Forum, Highlighting New Quality Productive Forces and Global Technological Cooperation

<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2025/04/14/8kz4zs7tb43.png"></figure>&nbsp;

Lattice NEXT makes its debut with SLICE NEXT FRONTIERS

AccuMedical has successfully defended its title in Group A and officially won the bid in the Hebei Provincial Inter-Provincial Alliance Centralized Volume-Based Procurement for Vascular Interventional Medical Consumables!<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2025/02/17/87zt60okmz.webp"></figure>

AccuMedical has successfully defended its title in Group A and officially won the bid in the Hebei Provincial Inter-Provincial Alliance Centralized Volume-Based Procurement for Vascular Interventional Medical Consumables!

AccuMedical officially won the bid in the Hebei Provincial Inter-Provincial Alliance Centralized Volume-Based Procurement！

<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2025/02/12/j6l0l96b6sm.png"></figure>&nbsp;

AccuMedical Wins the Bid in the Neurological Intervention Medical Consumables Procurement Alliance for Public Medical Institutions in Henan Province!

Recently, AccuMedical's Lattice Flow Diverter was awarded the 2024 Patent-Intensive Product Recognition, granted by Patent Protection Association of China. This honor is a high recognition of AccuMedical's innovation strength in the medical device field and a strong testament to the advanced technology and uniqueness of the Lattice product.&nbsp;<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2025/02/14/hdspt3jgcso.png"></figure>Lattice Flow Diverter&nbsp;Patent-intensive products refer to those that gain a competitive market advantage primarily from the patents they utilize. These products typically feature high patent protection strength, significant patent value contribution, and high dependence on patents for their competitiveness.Since its development, the Lattice Flow Diverter has been dedicated to solving complex cerebrovascular diseases with its innovative design concept. Its multiple core patented technologies encompass innovations in material science, precision manufacturing processes, and more. The integration of these technologies enables the device to excel in flow diversion, vascular reconstruction, and long-term stability, providing patients with safer and more effective treatment options.This recognition marks the Lattice Flow Diverter as a leader in intellectual property protection and technological innovation density in the industry. At the same time, this honor will inspire the company to continue increasing its research and development investment, further focusing on the medical device field, and contributing to solving more medical challenges and safeguarding human health.

AccuMedical's Lattice Flow Diverter Wins 2024 Patent-Intensive Product Recognition

On December 23, the Anhui Provincial Centralized Procurement Platform for Pharmaceuticals announced the Notification of Winning Bids for the Centralized Volume-Based Procurement of Intracranial Stents, Stent Retrievers, and Flow Diverters. AccuMedical's Lattice® Flow Diverter successfully won the bid!<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/12/24/q1pcuju08qs.png"></figure><figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/12/24/h3zymd7wr37.png"></figure>

Great News! Anhui Provincial Centralized Volume-Based Procurement Results Released!

Recently, the Beijing Municipal Bureau of Economy and Information Technology released the Notice on the Announcement of the New List of Beijing Enterprise Technology Centers for 2024. Following a rigorous review, evaluation, and public disclosure of the application materials, AccuMedical was honored to be included on the list.<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/12/25/z54z0mvn9kq.jpg"></figure><figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/12/25/21j2wky39li.png"></figure>The title of "Beijing Enterprise Technology Center" is an authoritative recognition awarded to enterprise technology centers that demonstrate strong innovation capabilities, effective innovation mechanisms, significant leadership, and meet specified criteria. It is a highly prestigious qualification for provincial and ministerial-level R&amp;D platforms, aligning with the requirements of innovation-driven development and economic structural adjustment.As an innovative medical device company dedicated to the field of neurointervention, AccuMedical adheres to a forward-looking R&amp;D principle guided by clinical insights, focusing on independent innovation in core technologies and products. By improving satisfaction for both physicians and patients, reducing surgical risks, and enhancing outcomes, the company continues to lead advancements in neurointerventional treatment.In recent years, AccuMedical has been awarded honors such as "National High-Tech Enterprise" and "National-Level 'Little Giant' Enterprise." Being recognized as a Beijing Enterprise Technology Center further reflects the government’s acknowledgment and affirmation of AccuMedical's R&amp;D innovation capabilities and technological achievements.Moving forward, the company will leverage this recognition as an opportunity to uphold the vision of technological self-reliance and strength. Guided by the corporate value of " Treat, as our own" AccuMedical will continue addressing unmet clinical needs in the field of cerebrovascular diseases, improving the accessibility of innovative medical technologies, and striving to meet the health needs of global cerebrovascular patients.<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/12/30/oc8pqi9f9x.jpg"></figure>

AccuMedical Recognized as a "Beijing Enterprise Technology Center."

In August 2024, the Beijing Municipal Science and Technology Commission&nbsp;， Administrative Commission of Zhongguancun Science Park issued the Notice on the Fund Management Measures to Support Enterprise Innovation Capability Enhancement in the Zhongguancun National Independent Innovation Demonstration Zone.According to Article 9 of the measures, support is provided for the first application of new technologies and products entering the market that address critical gaps in key fields and fill international or domestic technological voids. Eligible projects must feature international or domestic first-of-its-kind innovation, reach leading levels in their respective fields, drive technological advancement, and demonstrate potential for significant economic and social benefits. Additionally, intellectual property rights must be clear, with the enterprise possessing proprietary core technologies for the new products.AccuMedical's Lattice® Flow Diverter was selected for the 2024 First Market Entry of New Technology and Product Program due to its innovative achievements in the field of neurointervention.<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/12/12/itgxzd7ha8b.png"></figure>The Lattice® Flow Diverter, featuring a proprietary mechanical balloon delivery system and MIROR surface modification technology, is the first to extend the indications of flow diverters to the treatment of medium and small vertebral artery aneurysms, addressing a critical clinical gap. Among approved products in its class, Lattice® stands out with its broad indications, exceptional efficacy, and safety advantages. It significantly improves patient outcomes while simplifying and innovating surgical procedures. Its outstanding performance has earned widespread acclaim from physicians in clinical practice.Looking ahead, AccuMedical will continue to increase R&amp;D investment, drive technological innovation and product upgrades in the field of neurointervention, and deliver higher-quality products and services to patients and healthcare professionals worldwide.

Innovation Capability Recognized Again! AccuMedical Selected for the "2024 First Market Entry of New Technology and Product Program" by the Beijing Municipal Science and Technology Commission

Recently, the Ministry of Industry and Information Technology (MIIT) announced the list of the 6th batch of "National Specialized, Refined, Featured, and Innovative 'Little Giant' Enterprises," and AccuMedical Beijing Ltd. was included."Specialized, Refined, Featured, and Innovative" is a concept proposed by the MIIT in the 12th Five-Year Plan for Small and Medium Enterprises, and the "Little Giant" enterprises are its leaders. These enterprises focus on niche markets, possess strong innovation capabilities, have a high market share, control key technologies, and deliver excellent quality and efficiency.AccuMedical, with years of dedication in the field of neurointervention, has developed a comprehensive product line covering both hemorrhagic and ischemic stroke treatment products as well as access assistance devices. The company's self-developed core product, the Lattice® Flow Diverter, has expanded the indications of flow diverters to treat small[S1] &nbsp;and medium-sized vertebral artery aneurysms,&nbsp;filling a critical clinical gap.&nbsp;Compared to large enterprises, specialized and innovative "Little Giant" enterprises may be smaller in size, but they are "small yet sharp" and "small yet specialized," focusing on specific niche areas for the long term. The field of neurointervention, where AccuMedical specializes, is globally recognized as one with high research difficulty, high technical barriers, high clinical value, and large market potential.Currently, cerebrovascular diseases have become one of the leading health threats to middle-aged and elderly individuals, with high disability and mortality rates. Statistics show that approximately 1.5 million people die from cerebrovascular diseases in China every year, with intracranial aneurysms, often referred to as "time bombs," posing an ever-present risk of rupture and causing intracranial hemorrhage. The treatment of complex intracranial aneurysms presents challenges such as high surgical difficulty, high complication rates, and high recurrence rates.Compared to traditional treatments, the Lattice® Flow Diverter developed by AccuMedical is delivered via an interventional approach to the aneurysm-carrying artery. It isolates the aneurysm from the patent artery, redirecting blood flow away from the aneurysm, accelerating thrombosis within the aneurysm, and promoting endothelialization at the aneurysm neck, ultimately repairing the parent artery.The innovation of Lattice lies in its mechanical balloon delivery system, which actively expands the stent from within, ensuring precise deployment at the treatment site and allowing stent retrieval when necessary. This technology successfully reduces surgical complexity and recovery time, marking a new "automation era" in intracranial aneurysm treatment.Currently, Lattice is used in hundreds of hospitals across China, demonstrating exceptional clinical performance. Data shows a 91.4% aneurysm occlusion success rate and only a 0.8% in-stent restenosis rate at 12 months post-surgery. Its clinical application has notably reduced surgical complexity, shortened operation time, and improved patient outcomes.Innovation is the soul of "Specialized, Refined, Featured, and Innovative" enterprises. Only by firmly mastering the core industrial processes and key technologies can small and medium-sized enterprises unleash their tremendous potential. Currently, AccuMedical has applied for more than 118 patents, with 64 granted. These technological achievements provide a solid foundation for AccuMedical’s ongoing innovation and growth in the field of neurointervention.Previously, AccuMedical's innovation capabilities, strong technological accumulation, and clinical application results of its products have been widely recognized. The Lattice® Flow Diverter has been classified by the National Medical Products Administration (NMPA) as an "Innovative Medical Device" and has been fast-tracked through the "Green Channel" for approval. Additionally, in 2022, AccuMedical was recognized as a "Specialized, Refined, Featured, and Innovative" enterprise by Beijing, and in 2023, it was awarded the title of "National High-Tech Enterprise" and recognized by six departments, including the Beijing Science and Technology Commission, Development and Reform Commission, and Economic and Information Technology Bureau, as a new technology and product enterprise.Being selected as a "National Specialized, Refined, Featured, and Innovative 'Little Giant' Enterprise" is further affirmation of AccuMedical's investment in research and development and technological innovation. Moving forward, the company will continue to deepen its focus in the neurointervention field, leading with technological innovation, and providing better products and services to global patients and doctors, striving to drive the new development of China's medical device industry.

AccuMedical Recognized as National "Specialized, Refined, Featured, and Innovative 'Little Giant' Enterprise"

October 17, 2024，the National Medical Products Administration (NMPA) approved the registration of Lattice NEXT, the new generation of Flow Diverter produced by AccuMedical (Beijing) Co., Ltd.<figure class="image image_resized" style="width:597px;"><img src="/uploaded/accumedical/news/content/2024/11/13/glk78wov6t6.png"></figure>

Lattice NEXT, the new generation of AccuMedical’s Intracranial Flow Diverter approved for marketing by the NMPA!

On September 3, 2024, a series of events for the National Drug Safety Publicity Week were held in Beijing. The Medical Device Clinical Trial Management Symposium was hosted by the Department of Medical Device Registration of the National Medical Products Administration (NMPA), organized by the Beijing Municipal Drug Administration, and co-organized by Peking University's School of Medicine and Peking University Third Hospital. Lei Ping, a member of the NMPA Party Leadership Group and Deputy Administrator, attended the meeting and delivered a speech. Cao Wei, Director of the Beijing Municipal Drug Administration, also attended and gave a speech, while Li Dachuan, Deputy Director of the Medical Administration Department of the National Health Commission, and Lin Hang, Vice Mayor of Haidian District, participated in the event.<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/09/13/lrnkr8r8zjh.png"></figure>As a representative of domestic innovative medical device companies, AccuMedical was invited to attend the symposium and showcase its products.The symposium, themed "Strengthening Clinical Trial Quality Management and Promoting Medical Device Innovation and Development," aimed to publicize the policies and regulations regarding medical device clinical trial management, create a communication platform for clinical trial institutions, sponsors, researchers, and regulatory authorities, and promote the high-quality development of the medical device industry.Lei Ping, a member of the NMPA Party Leadership Group and Deputy Administrator, attended the symposium and delivered a speech. He emphasized that clinical trials are a critical method for evaluating the safety and effectiveness of medical devices. The NMPA will continue to improve the regulatory framework, strengthen the management of clinical trial institutions, and enhance the quality of clinical trials, working together with all stakeholders to foster a healthy clinical trial ecosystem.Cao Wei, Administrator of the Beijing Municipal Drug Administration, stated that the Bureau would implement the NMPA's requirements and plans in depth, coordinating development and safety. On the one hand, they will steadily promote "dual filing" for clinical trials and continually strengthen "dual inspections" to reduce risks associated with clinical trial processes. On the other hand, they will collaborate with multiple departments to optimize the business environment, improve evaluation and approval efficiency, and boost the high-quality development of the medical device industry.<figure class="image"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/09/13/wjss6hxroym.jpg"></figure>At the symposium, AccuMedical showcased its core product, the Lattice® Flow Diverter. Lei Ping, Deputy Administrator of the NMPA, Cao Wei, Administrator of the Beijing Municipal Drug Administration, as well as other drug administration leaders and experts, including Fu Wei, Director of Peking University Third Hospital, visited AccuMedical's booth and inquired about the product's R&amp;D and clinical applications.The Lattice® Flow Diverter is the first flow diverter to extend the indications to the treatment of medium and small vertebral artery aneurysms. By creatively integrating a mechanical balloon delivery system and MIROR surface modification technology, it represents a novel surgical approach for intracranial aneurysm treatment, which has rapidly developed and matured internationally over the past decade.Compared to traditional intrasaccular coiling procedures, AccuMedical's Lattice® Flow Diverter streamlines the treatment process for aneurysms. Its unique mechanical balloon system enhances precision and ensures smooth stent deployment, effectively addressing challenges such as stent kinking and vascular injury commonly seen in traditional surgeries. Additionally, the MIROR surface modification technology further enhances surgical safety and patient outcomes.Clinical data demonstrates that Lattice achieves a 91.4% aneurysm occlusion success rate and an in-stent restenosis rate of only 0.8% at 12-month post-surgery. By significantly reducing surgical complexity, it enhances the accessibility of intracranial aneurysm treatments. Today, Lattice is not only used in renowned top-tier hospitals in major cities but has also been widely adopted by county-level hospitals.Thanks to its deep technical foundation and continuous innovation in the neurointervention field, AccuMedical was recognized as a "Specialized, Refined, Featured, and Innovative" small and medium-sized enterprise by Beijing in 2022 and awarded "National High-Tech Enterprise" status in 2023.At the National Drug Safety Publicity Week opening ceremony, the NMPA stated that, in recent years, it has strictly implemented General Secretary Xi Jinping’s "Four Strictest" requirements, focusing on high-efficiency regulation to ensure high-level safety and promote high-quality development. China's pharmaceutical management regulatory system has been continuously improved, drug safety remains generally stable, and the pace of market approval for innovative drugs and medical devices has accelerated. The NMPA has also made solid progress in strengthening drug regulatory capabilities, effectively protecting and promoting public health.As an innovative company in the neurointervention field, AccuMedical aims to actively contribute to national medical innovation, ensuring high-level safety and the high-quality development of the industry, continuing to drive "genuine innovation and practical application" in the field of Chinese-made neurointerventional medical devices, and safeguarding public health and people’s lives with better products.

AccuMedical Invited to Attend the "National Drug Safety Publicity Week" Medical Device Clinical Trial Management Symposium

From August 9 to 11, Beijing hosted a major medical event&nbsp;– the 30th China International Medical Instrument and Equipment Exhibition &amp; Technical Exchange (China-Hospeq 2024). At this event, AccuMedical showcased its innovative product, the Lattice® Flow Diverter, showcasing the latest breakthroughs in neurointervention.<figure class="image"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/08/15/uvp723re2eq.jpg"></figure>&nbsp;A Feast of TechnologyChina-Hospeq 2024 was more than an exhibition; it was a platform for global medical experts to exchange ideas and share experiences. The event was hosted by the International Exchange and Cooperation Center of the National Health Commission, with over 200 high-quality enterprises from more than 10 countries and regions, including China, Germany, the United States, the Netherlands, and Sweden. These companies displayed products, technologies, and the latest solutions to address the health needs of various countries. Participants discussed ways to optimize the global medical trade and investment environment, promote deeper cooperation between Central Asia and China, and support regional health and well-being.At this international event, AccuMedical, as a representative in the field of neurointervention, attracted the attention of many domestic and international scholars and experts with its innovative Lattice® Flow Diverter technology.<figure class="image"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/08/15/5smxsw3xhwd.jpg"></figure><figure class="image"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/08/15/pd4tzfs0n9q.jpg"></figure><figure class="image"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/08/15/5jfwafbdxqy.jpg"></figure>Intracranial aneurysms, often referred to as "ticking time bombs" in the brain, have posed significant challenges for surgeons and patients due to the complexity of traditional treatment procedures and slow post-operative recovery over the past decades. The Lattice® Flow Diverter provides a new solution to this problem. For the first time, it extends the indications for flow diverters to include the treatment of medium and small vertebral artery aneurysms, addressing a critical gap in clinical needs.&nbsp;The innovative mechanical balloon system equipped on Lattice effectively addresses &nbsp;issues such as stent kinking and opening during surgery, ensuring precise positioning and smooth deployment. Additionally, the application of the MIROR surface modification technology resolves complications thay may arise from metal oxides on the surface of woven stents, significantly enhancing surgical safety.&nbsp;Bringing Chinese Innovation to the WorldClinical data shows that Lattice® Flow Diverter achieves a high aneurysm occlusion rate of 91.4% at 12 months post-operation, with an in-stent restenosis rate of only 0.8% at 12 months, which demonstrates Lattice’s superior surgical safety and favorable prognosis. Its unique design not only reduces surgical complexity but also improves the accessibility of intracranial aneurysm treatment.AccuMedical has not only made breakthroughs with Lattice® but also offers a product line that covers interventional devices and access devices for the treatment of hemorrhagic and ischemic strokes. To date, the company has filed 118 patent applications, with 63 granted, and seven products have been approved and entered the commercialization phase.<figure class="image"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/08/15/ko5c8nu9gge.jpg"></figure><figure class="image"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/08/15/nksl9st7p0k.jpg"></figure><figure class="image"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/08/15/jk9rwx2p7i.jpg"></figure><figure class="image"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/08/15/ojcnjb8r8up.jpg"></figure>China-Hospeq 2024 provided a global platform for domestic medical enterprises like AccuMedical. With frequent appearances on international medical exchange platforms, AccuMedical, as a new force in China’s neurointervention field, is injecting new vitality into the global research and development of cerebrovascular diseases.On the endless journey of exploring healthcare, the Lattice® Flow Diverter is just the beginning for AccuMedical. With more Chinese enterprises joining in, we have reason to believe that the future healthcare field will be even more exciting, with an increasing number of innovative products bringing more hope and possibilities to human health. Let us look forward to seeing the power of Chinese medical innovation shining brightly on the global stage.

"Exploring New Frontiers in Healthcare: AccuMedical's Lattice® Shines at China-Hospeq 2024"

“As a Chinese doctor, I deeply feel the increasing global attention and respect for China’s experiences and perspectives. Over the past 30 years, China has transformed from a follower to gradually aligning with international standards in the field of neurointervention. Through extensive research and innovation, China has contributed new evidence, devices, and experiences, which are of significant importance to scholars worldwide.” This was stated by Professor Liu Jianmin, Director of the Cerebrovascular Disease Center at the First Affiliated Hospital of the Naval Medical University (Shanghai Changhai Hospital), during a live interview at the World Live Neurovascular Conference (WLNC) in Istanbul. During this world-class academic exchange in the neurointervention field, Professor Liu Jianmin’s team demonstrated the Lattice® Flow Diverter, developed by AccuMedical, showcasing this innovative tool that directly addresses the clinical challenges of intracranial aneurysm treatment.<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/05/15/sqxn9ga03fc.png"></figure>&nbsp;Unraveling the Global Challenge of Intracranial Aneurysm TreatmentStroke is now the second leading cause of death worldwide, with China experiencing particularly high incidence rate, especially hemorrhagic strokes caused by intracranial aneurysms. Known as "ticking time bombs" in the brain, intracranial aneurysms are abnormal bulges in the arterial walls &nbsp;that can rupture at any time, leading to life-threatening intracranial hemorrhages. Data reveals that the prevalence of unruptured aneurysms in China’s population aged 35-75 reaches 7.0%, affecting nearly 100 million individuals. Once ruptured, the fatality rate from the first hemorrhage is around 35%, climbing to 60%–80% in case of recurrent bleeding.Faced with this high-risk condition, the medical community has been actively exploring new treatment approaches. Traditional craniotomies often impose greater financial, surgical, and psychological burdens on patients, with long recovery periods. However, advancements in neurointerventional technology have introduced a minimally invasive approach to treat unruptured aneurysms. Through vascular reconstruction with flow diverters, early intervention is now possible to “defuse the bomb” before rupture.The Lattice® Flow Diverter by AccuMedical, showcased at the WLNC, is one such “defusing tool”. Public information indicates that Lattice® is the first flow diverter of its kind to utilize mechanical balloon delivery technology and surface modification technology. Approved in October 2022 under the National Special Review Procedures for Innovative Medical Device (“Green Channel”), it is indicated for various aneurysms in the internal carotid and vertebral artery. Its approval includes the broadest indication in its class, making it the first product to extend indications to medium and small vertebral artery aneurysms.Clinical data highlights its impressive efficacy, with a 91.4% aneurysm occlusion success rate and only a 0.8% in-stent restenosis rate at 12 months post-surgery. During a live demonstration at WLNC, Professor Yang Pengfei from the First Affiliated Hospital of the Naval Medical University (Shanghai Changhai Hospital) introduced Lattice's structural and performance features, shared findings from LIFE pre-market clinical study, and demonstrated its operational techniques. The presentation garnered significant interest and attention from attending international experts.<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/05/15/ahgl5blp4h.png"></figure>In the live interview in Istanbul, Professor Liu Jianmin stated, "Innovation in China's neurointervention field is becoming increasingly prominent. This year, the surgeries we broadcast primarily used domestically manufacutred devices. Among them are globally leading devices such as the Lattice® Flow Diverter, whose innovative design surpasses existing products in many aspects. For example, it features a mechanical balloon delivery system with radiopaque markers and the MIROR surface modification technology. The mechanical balloon delivery system has an automatic expansion function, effectively resolving common issues like poor stent opening and inadequate wall apposition when deploying flow diverters in curved vessels. This innovative design simplifies the use of flow diverters in complex vescular scenarios.""Lattice®, through multiple groundbreaking technological innovations, has greatly reduced the surgical complexity for clinicians, shortened operation times, and improved patient recovery rates and surgical safety, ushering intracranial aneurysm treatment into an ‘automatic era’,” a representative from AccuMedical stated in a recent interview with CCTV News.The Lattice® Flow Diverter incorporates an innovative mechanical balloon system that effectively addresses challenges such as stent kinking and opening failure, and vascular damage caused by complex operations. This ensures precise positioning and smooth deployment, advancing intracranial aneurysm treatment into the "automatic" era. Additionally, with its advanced material selection and processing techniques, the MIROR surface modification technology resolves issues related to ischemic complications and cytotoxicity caused by metal oxides on woven stent surfaces, significantly enhancing surgical safety.&nbsp;China’s Self-developed Innovation Reaches the International StageThe WLNC is one of the largest and most internationalized neurointervention exchange platforms in the world. AccuMedical, as a representative of Chinese innovative medical devices, participated in this international event, showcasing the strength of China’s "new quality productive forces." In the past, due to the high technical barriers in stroke treatment, the development of neurointervention in China was limited. However, with continuous innovation and development by companies like AccuMedical, the trend of domestic production in the neurointervention field is emerging.According to Frost &amp; Sullivan data, from 2017 to 2022, the number of intracranial aneurysm interventional treatments in China increased from 44,000 to 84,000, with a compound annual growth rate (CAGR) of 13.8%. It is expected that by 2028, the number of procedures will reach 912,000, with a CAGR of 48.9%. This provides significant growth potential for domestic medical devices."Developing new quality productive forces&nbsp;cannot simply be about benchmarking foreign products. AccuMedical aims to break the 'imitation-following' technological path and continue investing in innovative R&amp;D to achieve 'true innovation and practical use' in the field of domestically produced neurointerventional medical devices," said an AccuMedical representative in a media interview.Public information shows that AccuMedical holds more than 100 domestic and international patents and has dual R&amp;D centers in China and the United States. With deep technical expertise and continuous innovation, AccuMedical has been recognized as a "Specialized, Refined, Featured, and Innovative" small and medium-sized enterprise by Beijing, a National High-Tech Enterprise, and is also one of the drafting units for the national standard for neurovascular thrombectomy stents. In addition to the Lattice® Flow Diverter showcased at the WLNC, AccuMedical's product line covers interventional devices and access devices for both hemorrhagic and ischemic stroke treatment, with seven products approved and entering the commercialization stage.<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/05/15/06m5kes34ze.png"></figure>&nbsp;A Promising Future for China’s Innovative Medical DevicesProfessor Liu Jianmin, in his live interview at the conference in Istanbul, commented, "The display of these innovative products indicates that China has transitioned from a follower to a contributor, researcher, and innovator in the field of neurointervention. We are now making important contributions to global neurointervention research and development. We are providing the latest high-level evidence, new devices, new concepts, and relevant experiences. I believe that in the post-pandemic era, as international exchanges become more routine, China's voice and contributions in neurointervention will have an increasingly significant global impact."

AccuMedical's Lattice® Debuts at WLNC, ushering intracranial aneurysm treatment into the "Automatic Mode" Era

Recently, the "Paracurve® Radial Access Guiding Catheter," independently developed by AccuMedical (Beijing) Co., Ltd., was approved for registration by the National Medical Products Administration (NMPA). The product has obtained a Class III medical device registration certificate with the registration number: NMPA 20243030848.This product is designed for introducing interventional devices into neurovascular, peripheral, and coronary arteries via the radial artery. It includes a guiding catheter and a selective catheter.AccuMedical is a commercialized innovative medical device company specializing in the field of neurointervention. Founded in 2017, AccuMedical is headquartered in Beijing with dual R&amp;D centers in China and the United States. AccuMedical has developed comprehensive businesses including R&amp;D, production, and marketing of neurointerventional devices for the treatment of hemorrhagic and ischemic strokes. Our mission is to offer a whole set of innovative solutions to a global population of cerebrovascular disease patients and physicians. As of March 2024, the company has filed 111 patent applications, with 65 patents granted.

AccuMedical’s Paracurve® Radial Access Guiding Catheter Approved for Marketing by NMPA

<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/05/11/9mym1wv8akl.jpg"></figure>From April 25 to 29, 2024, the Zhongguancun Forum Annual Conference was held in Beijing, with the theme "Innovation: Building a Better World."At this forum, major achievements in four key areas were highlighted: the cutting-edge frontier of global science and technology, the main economic battlefield, national strategic needs, and public health and people's lives. A series of world-class achievements and "cutting-edge technologies" innovations made their debut, including Nobel Laureate in Physiology or Medicine Barry Marshall sharing his views on "Curiosity-Driven Research," Fields Medalist Shing-Tung Yau discussing "Women and Scientific Development," and two Turing Award winners exploring the frontiers of artificial intelligence.At this national and international event, AccuMedical's core product, the Lattice® Flow Diverter, was showcased alongside the latest high-end medical innovations in China, earning recognition and praise from national and municipal leaders.<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/05/11/ltz8n8f1npj.jpg"></figure>Currently, AccuMedical holds over 100 domestic and international patents. Its neurointervention products cover all interventional devices and related access devices involved in the treatment of hemorrhagic and ischemic stroke. Six products have been approved and are rapidly progressing toward registration and commercialization.With deep technical expertise and continuous innovation in the neurointervention field, AccuMedical was named a "Specialized, Refined, Featured, and Innovative" small and medium-sized enterprise in Beijing in 2022 and a National High-Tech Enterprise in 2023.AccuMedical insists on integrating medicine and engineering to truly meet clinical patient needs. The Lattice® Flow Diverter is a new tool for the treatment of intracranial aneurysms, approved through the National Medical Products Administration's (NMPA) special review procedure for innovative medical devices. It is the first to expand the indication of flow diverters to treat small- and medium-sized vertebral artery aneurysms. It is now being used in many hospitals across China and has received high recognition from surgeons.<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/05/11/441gdh76wrf.jpg"></figure>Intracranial aneurysms, often called the brain’s "ticking time bombs" have traditionally been treated through craniotomy, a procedure with high risks and long recovery time. The Lattice® Flow Diverter, with its material and structural innovations, has ushered intracranial aneurysm treatment into an easier “automatic era”.Thanks to multiple groundbreaking innovations, the Lattice® Flow Diverter significantly enhances surgical efficacy and safety. Its mechanical balloon delivery system effectively minimizes vascular injury risks during procedures, ensures precise stent positioning, and achieves optimal wall apposition, thereby shortening surgery time and reducing complexity. Additionally, the MIROR surface modification technology effectively addresses issues with ischemic complications and cytotoxicity caused by metal oxides on woven stent surfaces, greatly improving surgical safety.Clinical data highlights its effectiveness in improving patient outcomes: at 12 months post-surgery, the Lattice® Flow Diverter achieves a 91.4% success aneurysm occlusion rate and an in-stent restenosis rate of just 0.8%.By greatly reducing the difficulty of treating past complex cases, the Lattice® Flow Diverter is making a significant contribution to improving public health and people's lives. This is the key significance of developing new quality productive forces in the medical field.<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/05/11/ohixa2mq5g.jpg"></figure>During an interview at the forum, AccuMedical’s CEO stated, “Developing new quality productive forces cannot simply be about benchmarking foreign products. AccuMedical aims to break the 'imitation-following' technological path and continue investing in innovative R&amp;D to achieve ‘true innovation and practical use’ in the field of neurointerventional medical devices, continuing to produce better products to safeguard public health.”

AccuMedical Shines at 2024 Zhongguancun Forum with Breakthrough Innovations, Capturing CCTV's Attention

On January 19, 2024, the U.S. Food and Drug Administration (FDA) approved the 510(k) application of Cosine® Distal Access Catheter produced by AccuMedical (Beijing) Co., Ltd. The approval information has been officially published in the FDA's premarket notification database.The FDA approval of the Cosine® Distal Access Catheter signifies that its safety and effectiveness have been recognized by U.S. regulatory authorities, offering patients more efficient and safer treatment options.<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/12/16/q0o8kuhm71e.png"></figure>The Cosine® Distal Access Catheter is designed for use in interventional procedures, facilitating the delivery of interventional devices in peripheral and neurovascular systems. It features a wide range of sizes, excellent torque control, minimal vascular irritation, and superior radiopacity, making it suitable for diverse surgical approaches.<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/12/16/fzkrt1zb02f.png"></figure>AccuMedical has been dedicated to the neurointervention field for many years. This FDA 510(k) clearance not only opens broader international markets for the company but also provides more comprehensive neurointerventional solutions for global cerebrovascular disease patients and physicians.

AccuMedical’s Cosine® Distal Access Catheter Approved for Marketing by FDA

Recently, the Office of the Leading Group for the National High-Tech Enterprise Recognition Management announced the fourth batch of 4,400 high-tech enterprises designated by Beijing’s certifying bodies in 2023. AccuMedical Beijing Ltd. was included in the list and designated as a National High-Tech Enterprise.&nbsp;<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/01/15/fuu83vr4yap.jpg"></figure>&nbsp;<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/01/15/5e3rul8zn4i.jpg"></figure>&nbsp;Science and technology are the primary productive forces and the primary source of competitive advantage. The National High-Tech Enterprise Recognition policy aims to guide enterprises in adjusting their industrial structure, promoting independent innovation, and fostering continuous innovation. This policy encourages enterprises to enhance their technological innovation capabilities. By achieving the “National High-Tech Enterprise” qualification, AccuMedical demonstrates its strong capabilities in independent research and development, the transformation of scientific and technological achievements, and its research and development management systems, all of which have been recognized and supported by the state. This recognition further highlights the company's advanced position in areas such as intellectual property, technological innovation, and the transformation of scientific achievements.AccuMedical has always focused on addressing unmet clinical needs in the field of cerebrovascular diseases, continuously innovating in products and techniques. The company has research and development centers in both Beijing, China and California, USA. By leveraging these dual R&amp;D centers, AccuMedical actively invests in cutting-edge technologies in neurointerventional medical devices, establishing an international, interdisciplinary, and experienced R&amp;D team and building a comprehensive R&amp;D system. The company has overcome key challenges and mastered core design, R&amp;D, and manufacturing technologies for neurointerventional medical devices, independently developing several core technologies. As of December 2023, AccuMedical has filed more than 88 patents, 43 of which have been granted. Many of its technologies are firsts in the world.&nbsp;AccuMedical adheres to the concept of technological self-reliance and independence, upholding its corporate value of “treating others as one would oneself.” The company is committed to providing innovative solutions for global patients with cerebrovascular diseases and doctors, aiming for "true innovation and true usage" in the localization of medical devices. The company remains focused on filling the unmet clinical needs in the field of cerebrovascular diseases, improving the accessibility of innovative medical technologies, and leading the innovative development of neurointerventional treatments.

AccuMedical was designated as a National High-Tech Enterprise

On December 8, 2023, the Beijing Municipal Science &amp; Technology Commission, Administrative Commission of Zhongguancun Science Park announced the second batch of the 2023 (totaling the 19th batch) list of recognized "Beijing New Technology, New Product, and New Service." Two products from AccuMedical Beijing Ltd., including the Flow Diverter and Distal Access Catheter, have successfully passed the certification as "Beijing New Technology &amp; Product (Service)".&nbsp;<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/pnefufwuem.png"></figure>Image: Announcement of the second batch of 2023 (totaling the 19th batch) of Beijing New Technology, New Product, and New Service certification.&nbsp;The Beijing New Technology &amp; Product (Service) recognition is a highly authoritative and influential recognition program. It selects advanced technological products and services with clear intellectual property rights, reliable quality, and broad market prospects from key leading technologies, strategic emerging industries, and modern service sectors, aligning with Beijing’s "High-End, Precision, and Cutting-Edge" economic structure. Recognized new technology and products (services) can enjoy government procurement and promotion support and be included in the national procurement platform for new technologies, products, and services.This recognition aims to promote the development of high-tech industries and the application of new technologies and products (services), providing momentum for enterprise innovation and research capability enhancement. Being selected this time is a strong endorsement by five departments, including the Beijing Science and Technology Commission and the Beijing Development and Reform Commission, of AccuMedical’s innovation and leadership in the field of neurointervention medical devices. The two successfully recognized products focus on the treatment of hemorrhagic cerebrovascular diseases and innovative solutions, addressing urgent clinical needs and already being applied in practice.&nbsp;<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/05/jin934f3zke.png"></figure><figure class="image"><img></figure>Image: AccuMedical selected in the second batch of 2023 (totaling the 19th batch) of Beijing New Technology, New Product, and New Service certification list.&nbsp;Founded in 2017, AccuMedical Beijing Ltd. is an innovative medical device company specializing in the field of neurointervention. Headquartered in Beijing with dual R&amp;D centers in China and the United States, AccuMedical has developed comprehensive businesses including R&amp;D, production, and marketing of neurointerventional devices for the treatment of hemorrhagic and ischemic strokes. Our mission is to offer a whole set of innovative solutions to a global population of cerebrovascular disease patients and physicians. Since its inception, AccuMedical has been dedicated to breakthroughs and advancements in key technologies and processes, focusing on high-barrier, high-clinical-value neurointervention products. As of December 2023, the company has filed over 88 patents, with 43 already granted, including multiple world-first technologies.The interventional treatment of intracranial aneurysms has entered the era of Flow Diverters (FD). Unlike traditional coil embolization within an aneurysm sac, FDs work by altering blood flow within the parent artery and reconstructing the vascular structure. This reduces the direct impact of blood flow on the aneurysm, leading to blood stagnation and thrombus formation within the aneurysm sac. Moreover, new endothelial cells grow over the surface of the FD at the aneurysm neck, eventually achieving complete aneurysm occlusion while reducing the risk of recurrence. According to the "Chinese Guidelines for Flow Diverter Treatment of Intracranial Aneurysms", FD treatment is highly effective and safe for unruptured wide-neck aneurysms in the internal carotid artery, including small, medium, large, and giant aneurysms. It is rated as a Class I recommendation with Level B evidence. AccuMedical’s Lattice Flow Diverter is currently the most widely approved FD in China, covering both anterior and posterior circulations. It is indicated for treating large/giant, medium, and small aneurysms, as well as saccular and fusiform aneurysms. This extensive applicability allows AccuMedical to offer broader treatment options for patients and address a wider range of cerebrovascular conditions.&nbsp;

AccuMedical Selected for Beijing's New Technology, New Product, and New Service Recognition List

On December 8, 2023, the 8th "Maker China" Beijing SME Innovation and Entrepreneurship Competition, also known as the "Maker Beijing 2023" Innovation and Entrepreneurship Competition, jointly organized by the Beijing Municipal Bureau of Economy and Information Technology and the Beijing Municipal Bureau of Finance, successfully concluded. AccuMedical Beijing Ltd.'s "Flow Diverter" project won Second Prize in the Pharmaceutical and Healthcare Industry Category and also secured Third Prize in the Shunyi District-level competition of "Maker Beijing 2023."&nbsp;<figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/11/7h5t0wsy77o.png"></figure><figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/11/zkzrz3ot55.png"></figure>Image: Announcement of the Top 10 Projects in the Eight Major Industries of "Maker Beijing 2023"&nbsp;The "Maker Beijing" competition is a significant brand event aimed at driving SME innovation and entrepreneurship while facilitating industry-finance collaboration. Now in its eighth consecutive year, the competition is jointly organized by the Beijing Municipal Bureau of Economy and Information Technology and the Beijing Municipal Bureau of Finance. It aligns with Beijing’s positioning as an international science and technology innovation hub, focuses on tackling key core technologies, and fosters synergy between innovation and industrial development, stimulating the intrinsic innovation momentum of tech enterprises. Su Guobin, a member of the Party Leadership Group and Deputy Director of the Beijing Municipal Bureau of Economy and Information Technology, stated that hosting the "Maker Beijing" competition is a key initiative to help SMEs integrate resources and drive innovation. In recent years, Beijing has actively implemented the central government’s policies supporting SME development, leveraging technological empowerment, fostering exemplary enterprises, and optimizing the service ecosystem. These efforts have significantly promoted SME growth. Moving forward, Beijing will continue to enhance the allocation of resources, including talent and funding, using the competition as a platform to encourage industry-academia-research collaboration, facilitate the integration of enterprises of different scales, improve service capabilities, and expand brand influence.As a technology-driven enterprise in the medical device sector, AccuMedical stood out in this year’s competition with its "Flow Diverter" project, demonstrating the company’s commitment to core technology and independent innovation. This achievement further highlights AccuMedical’s leading role in driving innovation in the field of neurointervention. The award-winning project focuses on the treatment of hemorrhagic cerebrovascular diseases and offers innovative clinical solutions. As an urgently needed medical device, it has already been applied in clinical practice, showcasing its effectiveness and impact.&nbsp;<figure class="image"><img></figure><figure class="image image_resized" style="width:599px;"><img src="/uploaded/accumedical/news/content/2025/06/11/vigtqqqfsk.png"></figure>Image: AccuMedical's "Maker Beijing 2023" Trophy and Certificate&nbsp;Founded in 2017, AccuMedical Beijing Ltd. is an innovative medical device company specializing in the field of neurointervention. Headquartered in Beijing with dual R&amp;D centers in China and the United States, AccuMedical has developed comprehensive businesses including R&amp;D, production, and marketing of neurointerventional devices for the treatment of hemorrhagic and ischemic strokes. Our mission is to offer a whole set of innovative solutions to a global population of cerebrovascular disease patients and physicians. Since its inception, AccuMedical has been dedicated to breakthroughs and advancements in key technologies and processes, focusing on high-barrier, high-clinical-value neurointervention products. As of December 2023, the company has filed over 88 patents, with 43 already granted, including multiple world-first technologies.The interventional treatment of intracranial aneurysms has entered the era of Flow Diverters (FD). Unlike traditional coil embolization within an aneurysm sac, FDs work by altering blood flow within the parent artery and reconstructing the vascular structure. This reduces the direct impact of blood flow on the aneurysm, leading to blood stagnation and thrombus formation within the aneurysm sac. Moreover, new endothelial cells grow over the surface of the FD at the aneurysm neck, eventually achieving complete aneurysm occlusion while reducing the risk of recurrence. According to the "Chinese Guidelines for Flow Diverter Treatment of Intracranial Aneurysms", FD treatment is highly effective and safe for unruptured wide-neck aneurysms in the internal carotid artery, including small, medium, large, and giant aneurysms. It is rated as a Class I recommendation with Level B evidence. AccuMedical’s Lattice Flow Diverter is currently the most widely approved FD in China, covering both anterior and posterior circulations. It is indicated for treating large/giant, medium, and small aneurysms, as well as saccular and fusiform aneurysms. This extensive applicability allows AccuMedical to offer broader treatment options for patients and address a wider range of cerebrovascular conditions.&nbsp;

Highlighting the Characteristics of a "Specialized, Refined, Distinctive, and Innovative" Enterprise, AccuMedical Wins Second Prize in the Pharmaceutical and Healthcare Industry Category at "Maker Beijing 2023"

AccuMedical Wins Second Prize in the Pharmaceutical and Healthcare Industry Category at "Maker Beijing 2023"

<figure class="image"><img src="/uploaded/accumedical/news/content/2024/11/01/epo361bbk8d.png"></figure>&nbsp;Recently, the National Medical Products Administration (NMPA) has approved the registration of the innovative product Intracranial Flow Re-Direction System produced by AccuMedical (Beijing) Co., Ltd.Lattice is an innovative flow diverter with mechanical balloon delivery system, which actively assists the opening of the stent from inside. The implant is made of cobalt-chromium alloy, which provides sufficient radial force and excellent wall apposition with the expansion of the mechanical balloon. Both the implant and mechanical balloons are treated with surface modification named MIROR (Metal Interface Reassembly for Optimizing Restenosis) technology, in order to reduce thrombogenicity and promote endothelialization.Lattice is intended for use in adult patients with wide-neck (aneurysm neck width ≥ 4mm or aneurysm/body ratio &lt; 2) non-ruptured intracranial aneurysms in the internal carotid artery (petrous to terminal) and vertebral artery, with vessel diameters ≥ 2.0mm and ≤ 5.6mm.Approved for marketing, Lattice will offer a theraupeutic treatment option for the physicians and patients.&nbsp;<figure class="image"><img src="/uploaded/accumedical/news/content/2023/11/16/teozl94005.png"></figure>&nbsp;Source:https://www.nmpa.gov.cn/yaowen/ypjgyw/ylqxyw/20221026140656139.html

Recently, the National Medical Products Administration (NMPA) has approved the registration of the innovative product Intracranial Flow Re-Direction System produced by AccuMedical (Beijing) Co., Ltd.

News